NEWPORT BEACH, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding warrants that the Company issued on January 27, 2025. Pursuant to the warrant inducement agreement, the investors have agreed to exercise the outstanding warrants to purchase an aggregate of 827,900 shares of the Company ...

MICHIGAN CITY, Ind., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Horizon Bancorp, Inc. (NASDAQ: HBNC) (“Horizon”), the parent company of Horizon Bank, today announced the pricing of the previously announced underwritten public offering of 6,207,000 shares of its common stock (the “Offering”), at a price to the public of $14.50 per share for aggregate gross proceeds of approximately $90,001,500 before deducting underwriting discounts and estimated offering expenses. In addition, Horizon has granted the underwriters a ...

MICHIGAN CITY, Ind., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Horizon Bancorp, Inc. (NASDAQ: HBNC) (“Horizon”), the parent company of Horizon Bank, announced today that it has launched an underwritten public offering of shares of its common stock (the “Offering”). Horizon expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering. Horizon intends to use the net proceeds from the Offering for general corporate purposes, including in s ...

Core Viewpoint - Solventum Corporation announced a secondary offering of 8,800,000 shares of its common stock, all being sold by 3M Company, with Solventum not receiving any proceeds from the offering [1]. Group 1: Offering Details - The offering consists of 8,800,000 shares of common stock with a par value of $0.01 per share [1]. - Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as underwriters for the offering [2]. - The shares are being offered under the Company's shelf registration statement on Form S-3, effective as of August 13, 2025 [3]. Group 2: Regulatory Information - The offering will be conducted only through a preliminary prospectus supplement filed with the SEC and the accompanying prospectus [3]. - Interested parties can obtain the preliminary prospectus supplement and accompanying prospectus for free via the SEC's EDGAR database or by contacting the underwriters directly [3]. Group 3: Company Background - Solventum aims to enable better healthcare through innovative solutions at the intersection of health, material, and data science [7].

Core Viewpoint - V2X, Inc. announced the sale of 2.0 million shares of its common stock by Vertex Aerospace, with V2X not participating in the sale and not receiving any proceeds from it [1] Group 1: Offering Details - The offering is underwritten by RBC Capital Markets, which will sell the shares through various methods including direct sales and brokerage transactions on the New York Stock Exchange [2] - V2X has agreed to repurchase 200,000 shares from the underwriter at the same price paid by RBC Capital Markets for the shares sold by Vertex Aerospace, using cash on hand for this repurchase [3] Group 2: Ownership and Governance Changes - After the offering, Vertex Aerospace will own approximately 32.3% of V2X's outstanding common stock, totaling 10,167,286 shares [4] - Following the transaction's closing, two directors designated by Vertex Aerospace will resign from V2X's Board of Directors by the 2026 Annual Meeting, and Vertex Aerospace will have limited rights regarding board committee designations and certain corporate actions [4] Group 3: Regulatory Information - A registration statement for the offering was declared effective by the SEC on September 12, 2022, and the offering will be conducted according to the prospectus contained in that registration statement [5]

Core Viewpoint - Celcuity Inc. has announced the pricing of its public offerings, including $175 million in convertible senior notes and approximately 1.84 million shares of common stock at $38.00 per share, aiming to raise a total of approximately $248.7 million for various corporate purposes [1][6]. Offering Details - The company is offering $175 million in 2.750% convertible senior notes due 2031, with an option for underwriters to purchase an additional $26.25 million to cover over-allotments [1][2]. - The common stock offering includes 1,836,842 shares priced at $38.00 each, with pre-funded warrants available at $37.999 per warrant [1][2]. Financial Terms - The convertible notes will accrue interest at 2.750% per year, payable semiannually, and will mature on August 1, 2031 [3]. - The initial conversion rate for the convertible notes is set at 19.4932 shares of common stock per $1,000 principal amount, equating to a conversion price of approximately $51.30 per share, representing a 35% premium over the common stock offering price [4]. Closing Timeline - The expected closing date for the convertible notes offering is August 1, 2025, while the common stock offering is anticipated to close on July 31, 2025, subject to customary closing conditions [5]. Use of Proceeds - The net proceeds from both offerings are estimated to be approximately $248.7 million, which will be used for working capital, clinical trial expenditures, and other general corporate purposes [6]. Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, with its lead candidate, gedatolisib, currently undergoing multiple clinical trials for various cancer indications [11].

Core Points - Braemar Hotels & Resorts Inc. declared a quarterly cash dividend of $0.05 per diluted share for its common stock for Q3 2025, equating to an annual rate of $0.20 per share, payable on October 15, 2025 [1] - The Board also declared a quarterly cash dividend of $0.3438 per diluted share for the 5.5% Series B Cumulative Convertible Preferred Stock, payable on October 15, 2025 [2] - A quarterly cash dividend of $0.5156 per diluted share was declared for the 8.25% Series D Cumulative Preferred Stock, also payable on October 15, 2025 [3] - Monthly cash dividends were declared for the Series E Redeemable Preferred Stock at $0.15625 per share, with payments scheduled for August 15, September 15, and October 15, 2025 [4] - For the Series M Redeemable Preferred Stock, monthly dividends of $0.17917, $0.17708, and $0.17500 per share were declared, with similar payment schedules [5][6][7] - As of June 30, 2025, there were 13,391,250 shares of Series E Redeemable Preferred Stock and 1,420,421 shares of Series M Redeemable Preferred Stock issued and outstanding [8]

Core Viewpoint - Upexi, Inc. has announced two significant capital-raising initiatives: an Equity Offering and a Note Offering, aimed at funding its business operations and expanding its cryptocurrency portfolio, particularly in Solana assets [1][3][6]. Equity Offering - The company has entered into securities purchase agreements for the sale of 12,457,186 shares of common stock at a price of $4.00 per share, generating approximately $50 million in gross proceeds before expenses [1][2]. - The closing of the Equity Offering is expected around July 14, 2025, pending customary closing conditions [2][5]. - Proceeds from the Equity Offering will be used for business operations, working capital, and to support the company's Solana treasury strategy [2][6]. Note Offering - Concurrently, Upexi has entered into agreements for the purchase of Convertible Notes with an aggregate principal amount of approximately $150 million, collateralized by Solana (SOL) [3][4]. - The Convertible Notes carry a 2.0% interest rate, payable quarterly, with a fixed conversion price of $4.25 per share and a maturity of 24 months [4][5]. - The closing of the Note Offering is anticipated around July 16, 2025, also subject to customary closing conditions [5]. Cryptocurrency Strategy - Upon closing the Note Offering, the company expects to hold approximately 1.65 million SOL, more than doubling its previously disclosed balance of 735,692 SOL [6]. - The net proceeds from the Equity Offering will be allocated to acquiring additional SOL in the coming weeks [6]. Company Overview - Upexi, Inc. specializes in the development, manufacturing, and distribution of consumer products and has diversified into the cryptocurrency sector [9].

Core Viewpoint - Houston American Energy Corp. has entered into a definitive agreement for a registered direct offering of 223,762 shares at a price of $10.60 per share, expected to raise approximately $2.37 million in gross proceeds [1][2]. Group 1: Offering Details - The offering is expected to close on or about June 20, 2025, subject to customary closing conditions [2]. - The net proceeds from the offering, estimated at approximately $2.1 million, will be used for general corporate purposes [2]. - The offering is made under a shelf registration statement previously filed and declared effective by the SEC [3]. Group 2: Placement Agent Agreement - The Company has appointed Univest Securities, LLC as the sole placement agent for the offering, entitled to an 8.0% fee on the proceeds and reimbursement for expenses not exceeding $10,000 [4]. Group 3: Equity Purchase Agreement - The Company and the institutional investor had discussions about an equity purchase agreement but decided not to execute it at this time [5]. - If reconsidered, the agreement could allow the Company to sell up to $30 million of common stock over a 24-month term, with the purchase price expected to be approximately 96% of the lowest daily volume-weighted average price during the three trading days following a purchase notice [5].

Core Viewpoint - Castellum, Inc. has successfully closed a public offering of 4,166,667 Units at a price of $1.20 per Unit, raising approximately $5.0 million in gross proceeds for working capital and general corporate purposes [1][2][3]. Group 1: Offering Details - The public offering consisted of Units, each comprising one share of common stock and one warrant to purchase one share of common stock [1]. - The warrants are immediately exercisable at a price of $1.22 per share and will expire 60 days from the date of issuance [1]. - The shares of common stock and warrants are immediately separable and were issued separately [1]. Group 2: Financial Information - Gross proceeds from the offering are approximately $5.0 million before deducting placement agent fees and offering expenses [2]. - The net proceeds will be utilized for working capital and general corporate purposes [2]. Group 3: Regulatory Information - A shelf registration statement on Form S-3 relating to the securities was previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. - The offering was conducted under a preliminary prospectus supplement and an accompanying prospectus that have been filed with the SEC [4].